Calliditas Therapeutics AB

CALTX

SE0010441584

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 07:43:44 2024-05-16 am EDT			5-day change	1st Jan Change
118.2 ^SEK	-0.21%		+7.13%	-6.61%

May. 15	European Equities Traded in the US as American Depositary Receipts Nudge Higher in Wednesday Trading	MT
May. 14	European Equities Traded in the US as American Depositary Receipts Nudge Higher in Tuesday Trading	MT

Calliditas Therapeutics AB Elects Molly Henderson as Member of the Board of Directors

June 25, 2020 at 12:30 pm EDT

Calliditas Therapeutics AB (publ) in its AGM held on June 25, 2020, elected Molly Henderson as member of the board of directors, for the period until the end of the next annual general meeting.

Latest news about Calliditas Therapeutics AB

European Equities Traded in the US as American Depositary Receipts Nudge Higher in Wednesday Trading	May. 15	MT
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Tuesday Trading	May. 14	MT
Calliditas Therapeutics Partner Offers Nefecon in China; Shares Rise	May. 14	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Wednesday Trading	May. 08	MT
Calliditas Therapeutics' Potential Head and Neck Cancer Treatment Meets Secondary Endpoints	May. 06	MT
Calliditas Therapeutics AB Announces Positive Topline Results of Phase 2 Head and Neck Cancer Trial with Lead NOX Inhibitor Candidate, Setanaxib	May. 06	CI
European Equities Traded in the US as American Depositary Receipts Rise Modestly Higher in Thursday Trading	May. 02	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading	Apr. 25	MT
Calliditas Therapeutics Says OLE Study Shows Treatment Response Consistent With Late-Stage NefIgArd Study's Findings	Apr. 24	MT
Calliditas Therapeutics AB Announces Positive NefIgArd Open Label Extension Results	Apr. 24	CI
European Equities Traded in the US as American Depositary Receipts Rebound in Monday Trading	Apr. 22	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading But End Week Down	Apr. 19	MT
Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024	Apr. 18	CI
Calliditas Therapeutics AB Presents Additional Data Analyses from the Phase 3 NeflgArd Trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024	Apr. 18	CI
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	Apr. 17	MT
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading	Apr. 15	MT
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading	Apr. 12	MT
European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading	Apr. 11	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	Apr. 10	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading	Apr. 09	MT
Calliditas Therapeutics AB to Present Nefecon Data At the ISN World Congress of Nephrology in Buenos Aires	Apr. 08	CI
Calliditas Therapeutics Gets US Patent Allowance for Cancer Treatment Inhibitor	Apr. 08	MT
European Equities Traded in the US as American Depositary Receipts Higher in Friday Trading, Close Out Week Lower	Apr. 05	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Thursday Trading	Apr. 04	MT
European Equities Traded in the US as American Depositary Receipts Rise Slightly in Wednesday Trading	Mar. 27	MT

Chart Calliditas Therapeutics AB

Duration

Period

More charts

Calliditas Therapeutics AB, formerly Pharmalink AB, is a Sweden-based specialty pharmaceutical company. It is focused on the development and commercialization of its product candidate Nefecon, a treatment for patients with inflammatory kidney disease (IgA nephropathy) who are at risk of progressing to renal failure. Nefecon is derived from the TARGIT technology, in which the capsule containing the active drug substance is coated in a way that the capsule remains intact as it passes through the stomach and intestine until it reaches the lower small intestine, where the release of content takes place. Nefeco combines time lag effect with a concentrated release of the active substance budesonide, within a designated target area.

Sector

Pharmaceuticals

Calendar

2024-08-12 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Calliditas Therapeutics AB

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

118.5 SEK

Average target price

208 SEK

Spread / Average Target

+75.53%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
CALLIDITAS THERAPEUTICS AB	-6.61%	595M
MERCK KGAA	+15.23%	78.37B
KYOWA KIRIN CO. LTD.	+11.98%	9.08B
SK BIOPHARMACEUTICALS CO., LTD.	-12.85%	5.06B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+54.35%	4.85B
INDIVIOR PLC	+15.53%	2.37B
BETTA PHARMACEUTICALS CO., LTD.	-20.85%	2.36B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+24.62%	2.27B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-29.25%	2.22B
VELOXIS PHARMACEUTICALS A/S	-0.50%	1.64B

Specialty & Advanced Pharmaceuticals